Abstract: Objective Theaim of this study was to compare clinical efficacy of lauromacrogol or anhydrous alcohol sclerotherapyin the treatment of patients with simple hepatic cysts(SHC) under ultrasound (US) guidance. Methods An consecutive 58 patients with SHC were encountered in the First Hospital of Yulin between June 2022 and January 2024, and were randomly divided into lauromacrogolgroup (n=28) and ethanol group (n=30). Patients received percutaneous transhepatic puncture under US guidance for cyst fluid extraction, then the sclerotherapy was carried out. Serum Golgi protein 73 (GP73), protein disulfide isomerase A3 (PDIA3) and chitosinase 3-like protein 1 (CHI3L1) levels were detected by ELISA, and post-operational pain was evaluated by visual analogue scale (VAS) score. Results At three days post-operationally, serumGP73, PDIA3 and CHI3L1 levels in patients with lauromacrogol sclerotherapy were (24.0±4.7)pg/L, (73.2±6.6)ng/ml and (41.7±4.5)ng/L, all much lower than [(36.7±6.1)pg/L, (92.8±7.9)ng/ml and (65.8±6.3)ng/L, respectively, P<0.05] in patients with ethanol sclerotherapy; at 2hour and 24hour, the resting and motion VAS scores in lauromacrogol group were all much lower than in ethanol group (P<0.05); incidence of adverse effects in lauromacrogol group was 14.3%, much lower than 36.7%(P<0.05) in ethanol group; by end of six months after treatment, disappearance rate of cysts in lauromacrogol group was 78.6%, much higher than 53.3%(P<0.05), and reduction of cyst volume was (93.7±9.7)%, much higher than [(83.0±9.2)%, P<0.05] in ethanol group. Conclusion Our results suggest that US-guided liver cyst puncture and fluid drainage with lauromacrogol sclerotherapy in dealing with patients with SHC has a satisfactory efficacy with less adverse effects.

Key words: Simple hepatic cysts, Lauromacrogol sclerothrapy, Cyst fluid drainage, Ultrasound guidance, Therapy